MARATTO

article · International Journal of Multidisciplinary Approach Research and Science

Projection of HIV/AIDS Mortality in Adamawa State through the Lee-Carter Model: Strides toward SDG-3

Abstract

Globally, HIV/AIDS remains a significant health concern, with profound impacts in developing nations, including Nigeria. This study aims to project mortality among HIV patients in Adamawa State using the Lee-Carter model to assess progress towards the third Sustainable Development Goal (SDG-3) - terminating AIDS by 2030. Mortality data for 2011-2020 on HIV patients aged 15-59 years receiving antiretroviral therapy (ART) was obtained from Adamawa State AIDS control database. The Lee-Carter model, using the Singular Value decomposition (SVD) for parameter estimation was fitted to estimate age-specific parameters. The time series component was forecast using ARIMA(0,1,0). Mortality data from 2011 to 2020 revealed a substantial 296% reduction in mortality, a testament to government and NGO interventions. The study delineates varied age group responses to improvements in mortality rates, pinpointing ages 55-59 as the most affected, while ages 15-19 exhibit the lowest mortality rates. Furthermore, individuals aged 20-24 show heightened responsiveness to general mortality improvements compared to other age cohorts. This work substantiates that Adamawa State has achieved substantial progress, exceeding the SDG-3 target of a 90% decline in HIV/AIDS patient mortality rate, setting a promising trajectory towards an AIDS-free society by 2030. However targeted strategies are still needed for older patients.

Research topics

  • HIV/AIDS Impact and Responses
  • Poverty, Education, and Child Welfare
  • Human Rights and Development

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.59653/ijmars.v3i02.1712

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.